Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Dalfampridine ER by Solaxa for Episodic Ataxia Type 2: Likelihood of Approval
Dalfampridine ER is under clinical development by Solaxa and currently in Phase II for Episodic Ataxia Type 2. According to...